RGEN News and Press, Repligen Corporation

2024-07-17 09:50:00 ET Summary The Fund (Investor Shares) returned -5.80% (net of fees) for the quarter, underperforming the Russell Midcap Index’s -3.35% return. The portfolio’s underperformance was primarily driven by stock selection. The Health Care and Industrial...

WALTHAM, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2024 financial results on Tuesday, July 30, 2024. The Company will issue a press release before the market opens and will host a conference call at ...

2024-07-13 06:56:10 ET Summary Repligen's Q1 revenue declined by 20% organically, driven by Covid-related business decline and reduced demand in China and protein business. Strong growth and pipelines in the core filtration business, with non-Covid filtration revenue surging by mo...

2024-07-04 04:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-07-02 13:15:22 ET More on S&P 500 Index: Earnings Bar Lowered As Q2 Reports Begin Growth Versus Disinflation Rate Cut By The Fed: Here Is What To Expect For Your Portfolio Citi says the S&P 500 has more upside in H2 and spotlights sectors it pref...

2024-06-21 14:00:08 ET Daniel Arias from Stifel Nicolaus issued a price target of $207.00 for RGEN on 2024-06-21 12:12:00. The adjusted price target was set to $207.00. At the time of the announcement, RGEN was trading at $123.16. The overall price target consensus is at...

2024-06-14 07:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-13 07:22:28 ET More on Repligen Repligen Stock: Still Quite Overvalued Repligen reports mixed Q1 results; reaffirms FY24 outlook Seeking Alpha’s Quant Rating on Repligen Read the full article on Seeking Alpha For further details see: ...

WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that its Board of Directors (“Board”) has approved the planned transition of Tony J. Hunt from Chief Executiv...

2024-05-30 15:03:56 ET Summary Repligen Corporation stock has dropped 15% since our initial analysis of the stock just over six months ago. The company has posted a couple of quarterly earnings reports since then, and the company's balance sheet is in solid shape. That said, R...